Verici Dx PLC Result of AGM (4438E)

TIDMVRCI

RNS Number : 4438E

Verici Dx PLC

29 June 2023

Verici Dx plc

("Verici Dx" or the "Company")

Result of AGM and voting results

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

The voting results of the AGM were as follows:

 
                 In Favour        Against    Withheld 
 Resolution     Votes       %    Votes   %     Votes 
             -----------  ----  ------      ---------- 
 1            58,326,878   100    10     0       0 
             -----------  ----  ------      ---------- 
 2            58,326,301   100    587    0       0 
             -----------  ----  ------      ---------- 
 3            57,252,764   100    10     0   1,074,114 
             -----------  ----  ------      ---------- 
 4            57,252,187   100    587    0   1,074,114 
             -----------  ----  ------      ---------- 
 

Enquiries:

 
Verici Dx                                                                www.v ericidx .com 
Sara Barrington, CEO                                                        Via Walbrook PR 
Julian Baines, Chairman 
 
Singer Capital Markets (Nominated Adviser                             Tel: [phone] 
 & Broker) 
Aubrey Powell / Sam Butcher 
 
Walbrook PR Limited                        Tel: [phone] or [e-mail] 
Paul McManus / Stephanie Cuthbert /                        Mob: [phone] / +44 7796 
 Sam Allen                                                                        794 663 / 
                                                                              07502 558 258 
 

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

Verici Dx's two lead products are Tutivia(TM), a post-transplant test focused upon acute cellular rejection, including sub-clinical rejection and Clarava(TM), a pre-transplant prognosis test for the risk of early acute rejection. These products seek to measure how a patient is likely to respond, and is responding, to a kidney transplant. These products are underpinned by extensive patented and published scientific research from the leading Mount Sinai Medical Center, for which the Company holds an exclusive worldwide licence.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBUGDLSUDDGXC

(END) Dow Jones Newswires

June 29, 2023 11:57 ET (15:57 GMT)